Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Phase 1

Completed

Conditions: Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Lymphoma
Chronic Myeloproliferative Disorders
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: umbilical cord blood transplantation
Drug: methylprednisolone

First Posted Date: 2003-02-06

Last Posted Date: 2020-07-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 55

Registration Number: NCT00054236

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-28

Last Posted Date: 2013-12-18

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 82

Registration Number: NCT00053092

Locations: 🇬🇧
Derriford Hospital, Plymouth, England, United Kingdom
🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Phase 2

Completed

Conditions: Myelodysplastic/Myeloproliferative Diseases
Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-28

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT00053287

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma
Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myeloproliferative Neoplasms

Interventions: Biological: anti-thymocyte globulin
Biological: G-CSF
Drug: busulfan
Drug: fludarabine phosphate
Drug: methotrexate
Drug: mycophenolate mofetil
Drug: tacrolimus
Procedure: allogeneic cell transplantation
Drug: allopurinol

First Posted Date: 2003-01-28

Last Posted Date: 2016-07-01

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 82

Registration Number: NCT00053196

Locations: 🇺🇸
Union Hospital Cancer Center at Union Hospital, Elkton MD, Maryland, United States
🇺🇸
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees, Voorhees, New Jersey, United States

and more 9 locations

S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Biological: therapeutic allogeneic lymphocytes
Drug: cyclosporine
Drug: fludarabine
Drug: mycophenolate mofetil
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-28

Last Posted Date: 2015-03-25

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 5

Registration Number: NCT00053014

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

and more 80 locations

Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: Lymphoma Trials Office

Target Recruit Count: 500

Registration Number: NCT00006250

Locations: 🇬🇧
St. Thomas' Hospital, London, England, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, England, United Kingdom
🇬🇧
Craigavon Area Hospital, Craigavon, Northern Ireland, United Kingdom

and more 56 locations

Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Leukemia Research Fund

Registration Number: NCT00004218

Locations: 🇮🇹
Ospedali Riuniti di Bergamo, Bergamo, Italy
🇮🇪
St. James' Hospital, Dublin, Ireland
🇬🇧
North Hampshire Hospital, Basingstoke, England, United Kingdom

and more 82 locations

Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

Phase 1

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Milton S. Hershey Medical Center

Registration Number: NCT00006100

Locations: 🇺🇸
Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

Phase 2

Completed

Conditions: Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Disease
Accelerated Phase of Disease
Chronic Phase of Disease

Interventions: Drug: Fludarabine Phosphate
Radiation: Total-Body Irradiation
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Cyclosporine
Drug: Mycophenolate Mofetil
Biological: Therapeutic Allogeneic Lymphocytes
Other: Laboratory Biomarker Analysis

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00003145

Locations: 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States

and more 5 locations

Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer

Phase 2

Withdrawn

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-11

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT00025519

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy